La Jol­la whips up some love for iron over­load drug with promis­ing da­ta snap­shot

With rev­enue trick­ling in from its first prod­uct and an NDA in place for a sec­ond, La Jol­la Phar­ma­ceu­ti­cal is ready to shine a bright light on the third can­di­date com­ing through its pipeline.

An in­ter­im analy­sis of a Phase II study sug­gests that LJPC-401 could sig­nif­i­cant­ly low­er the ex­cess iron lev­els in pa­tients with hered­i­tary he­mochro­mato­sis. The drug — a sub­cu­ta­neous in­jec­tion of syn­thet­ic hu­man hep­cidin — in­duced a mean re­duc­tion in TSAT from base­line of 42%, ver­sus 6% on place­bo (p<0.0001), mark­ing a clear score on the pri­ma­ry end­point.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.